KalVista Pharmaceuticals (KalVista Pharmaceuticals) Effective Interest Rate on Debt % : 0.00% (As of Jan. 2024)

View and export this data going back to 2015. Start your Free Trial

What is KalVista Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. KalVista Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Jan. 2024 was $0.00 Mil. KalVista Pharmaceuticals's average total debt for the quarter that ended in Jan. 2024 was $7.57 Mil. Therefore, KalVista Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Jan. 2024 was 0.00%.

KalVista Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for KalVista Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Effective Interest Rate on Debt % Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of KalVista Pharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, KalVista Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Effective Interest Rate on Debt % falls into.

KalVista Pharmaceuticals Effective Interest Rate on Debt % Calculation

KalVista Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Apr. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Apr. 2022 )	+	Total Debt (A: Apr. 2023 ))	/ count )
=	-1 * 0	/	( (8.188	+	8.232)	/ 2 )
=	-1 * 0	/	8.21
=	0.00 %

where

	Total Debt (A: Apr. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	7.211	+	0.977
=	8.188

	Total Debt (A: Apr. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	7.145	+	1.087
=	8.232

KalVista Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Jan. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Oct. 2023 )	+	Total Debt (Q: Jan. 2024 ))	/ count )
=	-1 * 0	/	( (7.694	+	7.444)	/ 2 )
=	-1 * 0	/	7.569
=	0.00 %

where

	Total Debt (Q: Oct. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	6.546	+	1.148
=	7.694

	Total Debt (Q: Jan. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	6.257	+	1.187
=	7.444

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Jan. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

KalVista Pharmaceuticals (NAS:KALV) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

KalVista Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (KalVista Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (NAS:KALV) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

Executives

Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Edward P. Feener	officer: Chief Scientific Officer	ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Thomas Andrew Crockett	director, officer: President and CEO	BUILDING 227, TETRICUS SCIENCE PARK, PORTON DOWN, SALISBURY, WILTSHIRE X0 SP4 0JQ
Paul K. Audhya	officer: Chief Medical Officer	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Benjamin L Palleiko	officer: CFO and Secretary	C/O KALVISTA PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLD 200, STE 2203, CAMBRIDGE MA 02139
Christopher Yea	officer: Chief Development Officer	ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Albert Cha	director	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Patrick Treanor	director	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Michael David Smith	officer: Senior VP, Development	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Andreas Maetzel	officer: Senior Vice President Medical	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Nancy Stuart	director	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Brian Jg Pereira	director	C/O ADVANCED MAGNETICS, INC., 61 MOONEY STREET, CAMBRIDGE MA 02138
Daniel B Soland	director	4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Sv Life Sciences Fund Iv (gp), L.p.	10 percent owner	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108